The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK

David Moore, Martin J Connock, Ed Wraith, Christine Lavery, David Moore, Martin J Connock, Ed Wraith, Christine Lavery

Abstract

Background: Mucopolysaccharidosis type I (MPS I) is a rare lysosomal storage disease subdivided into three phenotypes of increasing severity: Scheie, Hurler-Scheie and Hurler. To gauge the effectiveness of treatments and to determine the load likely to fall on health-care systems, it is necessary to understand the prevalence and natural progression of the disease especially with regard to life-expectancy. In general such data on the natural history of lysosomal storage diseases is sparse.

Methods: Analysis of prevalence and patient survival in MPS I disease using a unique longitudinal data set initiated and maintained over a period of more than 20 years by the Society for Mucopolysaccharide Diseases (UK).

Results: The birth prevalence of MPS I in England and Wales over the period 1981 to 2003 was 1.07/100,000 births and within +/- 5% of estimates reported in several studies that examined reasonably large populations. The median survival for MPS I patients (including all phenotypes irrespective of various treatments) was found by Kaplan-Meier analysis to be 11.6 years. This result was driven by the relatively poor survival of patients with the Hurler phenotype who, irrespective of any treatments received, had a median survival of 8.7 years; when censoring for receipt of bone marrow transplant (BMT) was implemented median survival of Hurler patients was diminished to 6.8 years. The difference between these survival curves was statistically significant by log rank test and can be attributed to beneficial effects of BMT and or selection of patients with superior prognosis for intervention with BMT. Survival curves for Hurler patients who received and did not receive BMT were very different. Probability of survival at 2 year after BMT was ~68% and was similar to this after 5 years (66%) and ten years (64%); the mean age of Hurler patients at receipt of BMT was 1.33 years (range 0.1 to 3 years). Follow up was insufficient to determine median survival of the milder phenotypes however, unsurprisingly, this was clearly superior to that for Hurler patients.

Conclusion: The birth prevalence of MPS I in England and Wales is 1.07/100,000 and the median survival for MPS I patients is 11.6 years.

Figures

Figure 1
Figure 1
Birth prevalence of MPS l. The horizontal line represents the overall birth prevalence (1.07/100,000 live births) for MPS I in England and Wales.
Figure 2
Figure 2
Kaplan Meier survival curves. A: All MPS I patients' survival from birth; B: Hurler patients' survival from birth; C: Hurler-Scheie patients' survival from birth; D: Hurler patients' survival from birth with and without censoring for bone marrow transplant; E: Hurler patients' survival from time of bone marrow transplantation; F: Hurler patients' survival from birth for those receiving or not receiving bone marrow transplant. Approximate 95% confidence intervals are shown for curves A-C, E and F but are omitted from D to aid clarity.

References

    1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Sly WS, editor. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2000. pp. 3421–3452.
    1. Wraith JE, Beck M, Lane R, van der PA, Shapiro E, Xue Y, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase) Pediatrics. 2007;120:e37–e46. doi: 10.1542/peds.2006-2156.
    1. Connock M, Burls AB, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, et al. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease. Health Technol Assess. 2006;10
    1. Burls A, Austin D, Moore D. Commissioning for rare diseases: view from the frontline. BMJ. 2005;331:1019–1021. doi: 10.1136/bmj.331.7523.1019.
    1. McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ. 2005;331:1016–1019. doi: 10.1136/bmj.331.7523.1016.
    1. Human Gene Mutation Database; Institute of Medical Genetics. Cardiff University Ref Type: Electronic Citation.
    1. Government Actuary Department Ref Type: Electronic Citation.
    1. Lowry RB, Renwick DH. Relative frequency of the Hurler and Hunter syndromes. New England Journal of Medicine. 1971;284:221–222.
    1. Lowry RB, Applegarth DA, Toone JR, MacDonald E, Thunem NY. An update on the frequency of mucopolysaccharide syndromes in British Columbia. Human Genetics. 1990;85:389–390. doi: 10.1007/BF00206770.
    1. Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Human Genetics. 1997;101:355–358. doi: 10.1007/s004390050641.
    1. Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in Western Australia. American Journal of Medical Genetics. 2003;123A:310–313. doi: 10.1002/ajmg.a.20314.
    1. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, Van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Human Genetics. 1999;105:151–156.
    1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–254. doi: 10.1001/jama.281.3.249.
    1. Hutchesson AC, Bundey S, Preece MA, Hall SK, Green A. A comparison of disease and gene frequencies of inborn errors of metabolism among different ethnic groups in the West Midlands, UK. J Med Genet. 1998;35:366–370.
    1. Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis. 2005;28:1011–1017. doi: 10.1007/s10545-005-0112-z.
    1. Boelens JJ, Wynn RF, O'Meara A, Veys P, Bertrand Y, Souillet G, et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007;40:225–233. doi: 10.1038/sj.bmt.1705718.
    1. National Institute for Health and Clinical Excellence: Appraising orphan drugs Ref Type: Electronic Citation.
    1. Pastores GM, Arn P, Beck M, Clarke JT, Guffon N, Kaplan P, et al. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Mol Genet Metab. 2007;91:37–47. doi: 10.1016/j.ymgme.2007.01.011.
    1. Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL. The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med. 2006;166:1938–1942. doi: 10.1001/archinte.166.18.1938.
    1. Society for Mucopolysaccharide diseases Ref Type: Electronic Citation.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera